Aptinyx (APTX) Gets a Buy Rating from William Blair

William Blair analyst Myles Minter reiterated a Buy rating on Aptinyx (APTX – Research Report) on June 16. The company's shares closed last Friday at $3.10. According to TipRanks.com, Minter is a 4-star analyst with an average return of 17.2% and a 62.7% success rate. Minter covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ionis Pharmaceuticals, and Minerva Neurosciences. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aptinyx with a $10.67 average price target, implying a 231.4% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target. See today’s analyst top recommended stocks >> Based on Aptinyx's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1 million and GAAP net loss of $14.23 million. In comparison, last year the company earned revenue of $818K and had a GAAP net loss of $14.71 million. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL. The post Aptinyx (APTX) Gets a Buy Rating from William Blair appeared first on TipRanks Financial Blog.

William Blair analyst Myles Minter reiterated a Buy rating on Aptinyx (APTX – Research Report) on June 16. The company's shares closed last Friday at $3.10.

According to TipRanks.com, Minter is a 4-star analyst with an average return of 17.2% and a 62.7% success rate. Minter covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ionis Pharmaceuticals, and Minerva Neurosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aptinyx with a $10.67 average price target, implying a 231.4% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.

Based on Aptinyx's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1 million and GAAP net loss of $14.23 million. In comparison, last year the company earned revenue of $818K and had a GAAP net loss of $14.71 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.

The post Aptinyx (APTX) Gets a Buy Rating from William Blair appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

What's Your Reaction?

like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0

Next Article

Translate Bio (TBIO) Gets a Buy Rating from William Blair

William Blair analyst Myles Minter reiterated a Buy rating on Translate Bio (TBIO – Research Report) yesterday. The company's shares closed last Friday at $18.36. According to TipRanks.com, Minter is a 4-star analyst with an average return of 17.2% and a 62.7% success rate. Minter covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ionis Pharmaceuticals, and Minerva Neurosciences. Translate Bio has an analyst consensus of Moderate Buy, with a price target consensus of $22.67. See today’s analyst top recommended stocks >> Translate Bio's market cap is currently $1.41B and has a P/E ratio of -68.10. The company has a Price to Book ratio of 5.29. Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TBIO in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. The post Translate Bio (TBIO) Gets a Buy Rating from William Blair appeared first on TipRanks Financial Blog.

William Blair analyst Myles Minter reiterated a Buy rating on Translate Bio (TBIO – Research Report) yesterday. The company's shares closed last Friday at $18.36.

According to TipRanks.com, Minter is a 4-star analyst with an average return of 17.2% and a 62.7% success rate. Minter covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ionis Pharmaceuticals, and Minerva Neurosciences.

Translate Bio has an analyst consensus of Moderate Buy, with a price target consensus of $22.67.

Translate Bio's market cap is currently $1.41B and has a P/E ratio of -68.10. The company has a Price to Book ratio of 5.29.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TBIO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.

The post Translate Bio (TBIO) Gets a Buy Rating from William Blair appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.